Phase 2 study of lifileucel TIL therapy in 220 patients with metastatic melanoma

This was a prospective, multicenter, phase 2 interventional study involving 220 patients with metastatic melanoma. The intervention was lifileucel (autologous tumor-infiltrating lymphocytes, LN-144) infusion administered after a nonmyeloablative lymphodepletion preconditioning regimen, followed by interleukin 2 (IL-2) administration. The study's primary outcome was objective response rate, but no specific efficacy results, such as response rates or duration of response, were provided in the input data.

No safety or tolerability data were reported, including rates of adverse events, serious adverse events, or treatment discontinuations. The study's follow-up duration was also not specified. The trial was sponsored by Iovance Biotherapeutics, Inc., the developer of the therapy.

Key limitations from the available information include the absence of reported efficacy outcomes, safety profile, and comparator data, which prevents any assessment of the treatment's benefit-risk profile. The phase 2 design and lack of reported results mean the evidence is preliminary. For clinical practice, this report indicates an ongoing investigation, but no conclusions about the therapy's effectiveness or safety can be drawn until complete trial results are published and peer-reviewed.